Standard Material Transfer Agreements 2 (SMTA2)
The SMTA 2 is a legally-binding contract between WHO and a company, laboratory or other institution that receives PIP Biological Materials (PIP BM) from a laboratory which is part of the Global Influenza Surveillance and Response System (GISRS).
The SMTA 2 ensures that manufacturers and research institutions that receive PIP BM share with WHO some of the benefits arising from their access to these materials. Its main purpose is to establish a structured process for an efficient and equitable access to vaccines and other life-saving products by all countries at the time of a pandemic. Through this contract, the entity commits to provide to WHO specific items that can be used to prepare for (e.g. training, technology license) or respond to (e.g. vaccines, antivirals, diagnostic kits) pandemic influenza.
There are three different categories of entities that sign an SMTA 2:
- Category A: influenza vaccine and antiviral manufacturers
- Category B: manufacturers of other pandemic related products (e.g. diagnostic tests and materials)
- Category C: all other recipients (universities, research institutions, bio-tech companies etc.)
The signatories, depending on their nature and capacity, may choose from a specific list of benefit options that are described in Annex 2 of the PIP Framework. Benefits include pandemic influenza vaccines, antiviral medicines and other pandemic related products or technologies.
A summary of the options available to each category of recipient of PIP Biological Materials can be found here:
For more information on the agreements signed to date and related benefits click here: